외래 종양학 주입 치료 시장 분석 및 예측(-2035년) : 유형별, 제품별, 서비스별, 기술별, 용도별, 최종 사용자별, 구성 요소별, 설치 유형별, 기기별, 솔루션별

Outpatient Oncology Infusion Market is anticipated to expand from $70.9 billion in 2024 to $198.6 billion by 2034, growing at a CAGR of approximately 13.1%. The Outpatient Oncology Infusion Market encompasses healthcare facilities providing cancer treatment through intravenous therapies outside hospital settings. This market focuses on patient convenience, cost-efficiency, and personalized care. Innovations in drug delivery and supportive care are enhancing treatment efficacy and patient experience. Rising cancer prevalence and advancements in biologics are propelling market growth, with an emphasis on improving clinical outcomes and expanding access to care.

The Outpatient Oncology Infusion Market is experiencing notable growth, propelled by advancements in cancer treatment protocols and patient-centric care models. The chemotherapy segment dominates, driven by its critical role in cancer management and the introduction of novel therapeutic agents. Immunotherapy, as a sub-segment, is rapidly gaining traction, reflecting its growing acceptance and effectiveness in enhancing patient outcomes. Targeted therapy follows closely, benefiting from personalized medicine approaches and technological innovations in drug delivery systems. The supportive care segment, focusing on symptom management and quality of life improvement, is witnessing increased attention, particularly in pain management and antiemetic therapies. Nutritional support and psychosocial interventions are also emerging as significant sub-segments, aligning with holistic treatment paradigms. The integration of digital health solutions, such as telemedicine and remote monitoring, is transforming patient engagement and care delivery, offering promising opportunities for market players to enhance service accessibility and operational efficiency.

The Outpatient Oncology Infusion Market is experiencing a dynamic shift in market share, influenced by strategic pricing and innovative product launches. Key players are adopting competitive pricing strategies to capture a larger market segment, focusing on cost-effective solutions that cater to diverse patient needs. New product launches are pivotal, with companies introducing advanced infusion therapies that promise improved patient outcomes and enhanced convenience. This trend is further bolstered by a growing emphasis on personalized medicine, driving the demand for tailored oncology treatments in outpatient settings. Competition in the Outpatient Oncology Infusion Market is intense, with top firms vying for dominance through innovation and strategic alliances. Benchmarking reveals a landscape where regulatory influences play a critical role, shaping market dynamics and driving compliance. Regulatory frameworks in North America and Europe are particularly stringent, impacting product approval timelines and market entry strategies. Companies are investing in compliance and quality assurance to navigate these challenges and capitalize on emerging opportunities. The market is poised for growth, driven by technological advancements and a robust pipeline of oncology infusion therapies.

Geographical Overview:

The outpatient oncology infusion market is witnessing substantial growth across various regions, each with unique opportunities. North America leads, driven by advanced healthcare infrastructure and a growing prevalence of cancer. The region's focus on innovative treatment modalities further propels market expansion. Europe follows, with increasing government initiatives and funding for cancer treatment fostering a conducive environment for market growth. In Asia Pacific, the market is expanding rapidly, supported by rising healthcare expenditure and a growing patient population. Countries like China and India are emerging as key players, with significant investments in healthcare infrastructure. Latin America presents untapped potential, with countries such as Brazil and Mexico investing in healthcare advancements. The Middle East & Africa are also emerging as promising markets, with increasing awareness and access to cancer treatments driving growth. These regions are recognizing the importance of enhancing oncology care to meet the rising demand for outpatient infusion services.

Global tariffs and geopolitical risks are profoundly influencing the Outpatient Oncology Infusion Market, with Japan, South Korea, China, and Taiwan at the forefront. Japan and South Korea are enhancing domestic pharmaceutical capabilities to mitigate tariff-induced cost pressures, while China is navigating export restrictions by bolstering its local biotech sector. Taiwan, a key player in medical device manufacturing, remains vulnerable to US-China tensions yet continues to innovate in precision oncology tools. The global parent market is experiencing robust growth, driven by technological advancements and increasing cancer prevalence. By 2035, the market is anticipated to flourish, contingent on resilient supply chains and strategic regional partnerships. Middle East conflicts may exacerbate global supply chain disruptions and elevate energy prices, influencing operational costs and market dynamics.

Key Trends and Drivers:

The outpatient oncology infusion market is experiencing robust growth driven by several key trends and drivers. The increasing prevalence of cancer globally is a primary driver, necessitating more accessible and efficient treatment options. Outpatient infusion centers offer a cost-effective alternative to inpatient care, aligning with healthcare systems' focus on reducing costs while maintaining quality care. Technological advancements in infusion therapies are enhancing treatment efficacy and patient experience. Innovations such as targeted therapies and immunotherapies are becoming more prevalent, necessitating specialized infusion services. This trend is supported by ongoing research and development in oncology, leading to the introduction of novel therapeutics that require outpatient administration. Patient-centric care models are increasingly prioritized, with outpatient settings offering a more convenient and comfortable environment for patients. This shift is driven by the desire to improve patient outcomes and satisfaction. Additionally, regulatory support for outpatient services is bolstering market growth, as governments and healthcare organizations recognize the benefits of decentralizing cancer care. Opportunities abound for providers that can offer integrated, patient-focused services in this evolving landscape.

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Component
• 2.8 Key Market Highlights by Installation Type
• 2.9 Key Market Highlights by Equipment
• 2.10 Key Market Highlights by Solutions

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Chemotherapy
  • 4.1.2 Immunotherapy
  • 4.1.3 Targeted Therapy
  • 4.1.4 Hormonal Therapy
  • 4.1.5 Biological Therapy
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Infusion Pumps
  • 4.2.2 Intravenous Sets
  • 4.2.3 Catheters
  • 4.2.4 Needles
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Patient Management
  • 4.3.2 Treatment Planning
  • 4.3.3 Follow-up Care
  • 4.3.4 Nutritional Support
  • 4.3.5 Psychological Support
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Smart Infusion Systems
  • 4.4.2 Wearable Infusion Devices
  • 4.4.3 Automated Infusion Systems
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Breast Cancer
  • 4.5.2 Lung Cancer
  • 4.5.3 Colorectal Cancer
  • 4.5.4 Prostate Cancer
  • 4.5.5 Blood Cancer
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Hospitals
  • 4.6.2 Ambulatory Surgical Centers
  • 4.6.3 Specialty Clinics
  • 4.6.4 Homecare Settings
• 4.7 Market Size & Forecast by Component (2020-2035)
  • 4.7.1 Software
  • 4.7.2 Hardware
  • 4.7.3 Services
• 4.8 Market Size & Forecast by Installation Type (2020-2035)
  • 4.8.1 New Installation
  • 4.8.2 Retrofit
• 4.9 Market Size & Forecast by Equipment (2020-2035)
  • 4.9.1 Infusion Chairs
  • 4.9.2 Monitoring Devices
• 4.10 Market Size & Forecast by Solutions (2020-2035)
  • 4.10.1 Patient Monitoring Solutions
  • 4.10.2 Data Management Solutions

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Component
    • 5.2.1.8 Installation Type
    • 5.2.1.9 Equipment
    • 5.2.1.10 Solutions
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Component
    • 5.2.2.8 Installation Type
    • 5.2.2.9 Equipment
    • 5.2.2.10 Solutions
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Component
    • 5.2.3.8 Installation Type
    • 5.2.3.9 Equipment
    • 5.2.3.10 Solutions
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Component
    • 5.3.1.8 Installation Type
    • 5.3.1.9 Equipment
    • 5.3.1.10 Solutions
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Component
    • 5.3.2.8 Installation Type
    • 5.3.2.9 Equipment
    • 5.3.2.10 Solutions
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Component
    • 5.3.3.8 Installation Type
    • 5.3.3.9 Equipment
    • 5.3.3.10 Solutions
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Component
    • 5.4.1.8 Installation Type
    • 5.4.1.9 Equipment
    • 5.4.1.10 Solutions
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Component
    • 5.4.2.8 Installation Type
    • 5.4.2.9 Equipment
    • 5.4.2.10 Solutions
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Component
    • 5.4.3.8 Installation Type
    • 5.4.3.9 Equipment
    • 5.4.3.10 Solutions
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Component
    • 5.4.4.8 Installation Type
    • 5.4.4.9 Equipment
    • 5.4.4.10 Solutions
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Component
    • 5.4.5.8 Installation Type
    • 5.4.5.9 Equipment
    • 5.4.5.10 Solutions
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Component
    • 5.4.6.8 Installation Type
    • 5.4.6.9 Equipment
    • 5.4.6.10 Solutions
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Component
    • 5.4.7.8 Installation Type
    • 5.4.7.9 Equipment
    • 5.4.7.10 Solutions
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Component
    • 5.5.1.8 Installation Type
    • 5.5.1.9 Equipment
    • 5.5.1.10 Solutions
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Component
    • 5.5.2.8 Installation Type
    • 5.5.2.9 Equipment
    • 5.5.2.10 Solutions
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Component
    • 5.5.3.8 Installation Type
    • 5.5.3.9 Equipment
    • 5.5.3.10 Solutions
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Component
    • 5.5.4.8 Installation Type
    • 5.5.4.9 Equipment
    • 5.5.4.10 Solutions
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Component
    • 5.5.5.8 Installation Type
    • 5.5.5.9 Equipment
    • 5.5.5.10 Solutions
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Component
    • 5.5.6.8 Installation Type
    • 5.5.6.9 Equipment
    • 5.5.6.10 Solutions
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Component
    • 5.6.1.8 Installation Type
    • 5.6.1.9 Equipment
    • 5.6.1.10 Solutions
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Component
    • 5.6.2.8 Installation Type
    • 5.6.2.9 Equipment
    • 5.6.2.10 Solutions
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Component
    • 5.6.3.8 Installation Type
    • 5.6.3.9 Equipment
    • 5.6.3.10 Solutions
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Component
    • 5.6.4.8 Installation Type
    • 5.6.4.9 Equipment
    • 5.6.4.10 Solutions
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Component
    • 5.6.5.8 Installation Type
    • 5.6.5.9 Equipment
    • 5.6.5.10 Solutions

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Genesis Care
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 21st Century Oncology
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 American Oncology Network
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Oncology Consultants
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Tennessee Oncology
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Florida Cancer Specialists
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Texas Oncology
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 The US Oncology Network
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 New York Cancer and Blood Specialists
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Oncology Hematology Care
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Compass Oncology
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Virginia Oncology Associates
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Rocky Mountain Cancer Centers
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Arizona Oncology
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Minnesota Oncology
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Maryland Oncology Hematology
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Hematology Oncology Associates of Central New York
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Southeast Radiation Oncology Group
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Cancer & Hematology Centers of Western Michigan
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Oncology Specialists
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us